Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic Exclusivity Debate Continues At FDA: What Counts As A Forfeit?

Executive Summary

FDA is continuing its case-by-case review of the 180-day exclusivity status for ANDAs as they approach marketing - most recently for generics of Bayer's Precose (acarbose), King's Altace (ramipril) and Roche's Kytril (granisetron)
Advertisement

Related Content

Altace ANDAs On Hold Till June; Colbalt Gets Exclusivity, Not “Parking” Ticket
Altace ANDAs On Hold Till June; Colbalt Gets Exclusivity, Not “Parking” Ticket
Generic Exclusivity Triggers May Force Re-evaluation Of Brand/Generic Deals
Generic Exclusivity Triggers May Force Re-evaluation Of Brand/Generic Deals
180-Day Generic Exclusivity Decisions Could Follow Norvasc Model, FDA Says
180-Day Generic Exclusivity Decisions Could Follow Norvasc Model, FDA Says
Mylan Nifedipine Settlement Revised Certification To Paragraph III, FDA Says
Advertisement
UsernamePublicRestriction

Register

PS048911

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel